CASP3 and myelodysplastic syndrome: The CASP3 (Fig. 6H, 2.09 ± 0.26-fold vs. 0.88 ± 0.3-fold, P = 0.03) and BAX (Fig. 6H, 2.0 ± 0.35-fold vs. 1.08 ± 0.14-fold, P = 0.03) mRNA levels were significantly upregulated in higher-risk MDS BM EPCs compared to lower-risk MDS BM EPCs.